[
  {
    "ts": "2025-05-08T16:38:00+00:00",
    "headline": "Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains",
    "summary": "VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.",
    "url": "https://finance.yahoo.com/news/viatris-q1-earnings-revenues-beat-163800664.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "62bb7fd3-8df6-3933-aa1a-052ea66d7cba",
      "content": {
        "id": "62bb7fd3-8df6-3933-aa1a-052ea66d7cba",
        "contentType": "STORY",
        "title": "Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains",
        "description": "",
        "summary": "VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.",
        "pubDate": "2025-05-08T16:38:00Z",
        "displayTime": "2025-05-08T16:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d7sHwZPFV1U3B4BGoNlXfg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k5CBlnqEqKxZI1S0BuG_ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-q1-earnings-revenues-beat-163800664.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-q1-earnings-revenues-beat-163800664.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T13:54:40+00:00",
    "headline": "Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%",
    "summary": "Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/viatris-nasdaq-vtrs-reports-sales-135440090.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "442cd93c-b49d-33a1-9293-2352c9469cbc",
      "content": {
        "id": "442cd93c-b49d-33a1-9293-2352c9469cbc",
        "contentType": "STORY",
        "title": "Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%",
        "description": "",
        "summary": "Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.",
        "pubDate": "2025-05-08T13:54:40Z",
        "displayTime": "2025-05-08T13:54:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VTRS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZ5PSZg5aKFn_8IHve8fGQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bPZw8EZ18ugKQPfipbnLw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-nasdaq-vtrs-reports-sales-135440090.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-nasdaq-vtrs-reports-sales-135440090.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T13:30:30+00:00",
    "headline": "Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say",
    "summary": "While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finance.yahoo.com/news/viatris-vtrs-reports-q1-earnings-133030013.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8a57fa9a-edcc-34d6-984c-6e718379c305",
      "content": {
        "id": "8a57fa9a-edcc-34d6-984c-6e718379c305",
        "contentType": "STORY",
        "title": "Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say",
        "description": "",
        "summary": "While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
        "pubDate": "2025-05-08T13:30:30Z",
        "displayTime": "2025-05-08T13:30:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VQTahvfxY5Qw8Ld_ibk8SA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uIfVIw8I.vo0_xUfE1XIrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-vtrs-reports-q1-earnings-133030013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-vtrs-reports-q1-earnings-133030013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T12:15:12+00:00",
    "headline": "Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates",
    "summary": "Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/viatris-vtrs-beats-q1-earnings-121512571.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c4a9e252-f7ac-3aee-8c0e-f8caa2d59b0f",
      "content": {
        "id": "c4a9e252-f7ac-3aee-8c0e-f8caa2d59b0f",
        "contentType": "STORY",
        "title": "Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates",
        "description": "",
        "summary": "Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-05-08T12:15:12Z",
        "displayTime": "2025-05-08T12:15:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CWazdtIY_OpVNPwmJabcjQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S8TA.VI0J48dh2TXqKSlJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-vtrs-beats-q1-earnings-121512571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-vtrs-beats-q1-earnings-121512571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "AUNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T11:10:31+00:00",
    "headline": "Viatris: Q1 Earnings Snapshot",
    "summary": "CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $3.04 billion in its first quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of $2.55.",
    "url": "https://finance.yahoo.com/news/viatris-q1-earnings-snapshot-111031145.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "9b5a2649-c2e0-3e4d-a411-c379cf3dc9f2",
      "content": {
        "id": "9b5a2649-c2e0-3e4d-a411-c379cf3dc9f2",
        "contentType": "STORY",
        "title": "Viatris: Q1 Earnings Snapshot",
        "description": "",
        "summary": "CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $3.04 billion in its first quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of $2.55.",
        "pubDate": "2025-05-08T11:10:31Z",
        "displayTime": "2025-05-08T11:10:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-q1-earnings-snapshot-111031145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-q1-earnings-snapshot-111031145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T10:59:00+00:00",
    "headline": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook",
    "summary": "Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1].",
    "url": "https://finance.yahoo.com/news/viatris-reports-first-quarter-2025-105900772.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "7108cd4f-63af-3477-9ee8-e1f114bb82d1",
      "content": {
        "id": "7108cd4f-63af-3477-9ee8-e1f114bb82d1",
        "contentType": "STORY",
        "title": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1].",
        "pubDate": "2025-05-08T10:59:00Z",
        "displayTime": "2025-05-08T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/69fe213168921c430642389fc1d1489b",
          "originalWidth": 155,
          "originalHeight": 200,
          "caption": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sjeTIy_ZQOnd70o9Nrmoog--~B/aD0yMDA7dz0xNTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/69fe213168921c430642389fc1d1489b.cf.webp",
              "width": 155,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FUExbLef3kbj.bt4w0ldOg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/69fe213168921c430642389fc1d1489b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-reports-first-quarter-2025-105900772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-reports-first-quarter-2025-105900772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T10:45:00+00:00",
    "headline": "Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 inves",
    "url": "https://finance.yahoo.com/news/viatris-announces-positive-results-phase-104500745.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2f7e97c3-50d8-3734-a1c9-cf844f075202",
      "content": {
        "id": "2f7e97c3-50d8-3734-a1c9-cf844f075202",
        "contentType": "STORY",
        "title": "Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 inves",
        "pubDate": "2025-05-08T10:45:00Z",
        "displayTime": "2025-05-08T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8X7v9Q2NGJ8HikeN5BEPA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g4h5fNpHKz3PzdbDqFxRYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-results-phase-104500745.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-results-phase-104500745.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-08T10:30:00+00:00",
    "headline": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of",
    "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-103000526.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1277bfcd-afe3-3295-bff9-1b0f6b8aa9da",
      "content": {
        "id": "1277bfcd-afe3-3295-bff9-1b0f6b8aa9da",
        "contentType": "STORY",
        "title": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of",
        "pubDate": "2025-05-08T10:30:00Z",
        "displayTime": "2025-05-08T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8X7v9Q2NGJ8HikeN5BEPA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g4h5fNpHKz3PzdbDqFxRYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-103000526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-positive-top-line-103000526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]